Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 22, 2022
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Woroń , J. (2022). Komentarz. Medycyna Faktów , 15(4(57), 410-411. https://doi.org/10.24292/01.MF.0422.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010; 70(4): 489-512. http://doi.org/10.2165/11203790-000000000-00000.
2. Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs. 2011; 71(3): 349-61. http://doi.org/10.2165/11206060-000000000-00000.
3. Hermansen K, Kipnes M, Luo E et al; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9(5): 733-45. http://doi.org/10.1111/j.1463-1326.2007.00744.x.
4. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther. 2007; 29(12): 2614-34. http://doi.org/10.1016/j.clinthera.2007.12.034.
5. Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc). 2007; 43(10): 681-9. http://doi.org/10.1358/dot.2007.43.10.1136901.
2. Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs. 2011; 71(3): 349-61. http://doi.org/10.2165/11206060-000000000-00000.
3. Hermansen K, Kipnes M, Luo E et al; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9(5): 733-45. http://doi.org/10.1111/j.1463-1326.2007.00744.x.
4. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther. 2007; 29(12): 2614-34. http://doi.org/10.1016/j.clinthera.2007.12.034.
5. Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc). 2007; 43(10): 681-9. http://doi.org/10.1358/dot.2007.43.10.1136901.